Cellectis wins patents for CRISPR gene editing in T-cells – BioPharma-Reporter.com
BioPharma-Reporter.com |
Cellectis wins patents for CRISPR gene editing in T-cells
BioPharma-Reporter.com “CRISPR is a gene editing tool. It allows the engineering of the T cells, like any other gene editing tool, in order to add or delete a specific characteristic in T-cell genome,” a spokesperson from the French cell therapy firm told this publication … The Silver Lining In CRISPR Therapeutics AG (CRSP), Organovo Holdings, Inc. (ONVO) Rupert Beale Crispr Therapeutics AG (CRSP) Holdings Boosted by Global Thematic Partners LLC |
